Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sanofi (SNY : NSDQ)
 
 • Company Description   
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Number of Employees: 95,442

 
 • Price / Volume Information   
Yesterday's Closing Price: $54.40 Daily Weekly Monthly
20 Day Moving Average: 2,301,777 shares
Shares Outstanding: 2,527.23 (millions)
Market Capitalization: $137,481.08 (millions)
Beta: 0.50
52 Week High: $58.10
52 Week Low: $46.93
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.29% 9.82%
12 Week 2.54% 15.25%
Year To Date 8.58% 32.65%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
54 RUE LA BOETIE
-
PARIS,I0 75008
-
ph: 33-1-53-77-44-00
fax: 33-1-53-77-43-03
ir@sanofi.com http://www.sanofi.com
 
 • General Corporate Information   
Officers
Paul Hudson - Chief Executive Officer
Serge Weinberg - Chairman
Christophe Babule - Executive Vice President; Chief Financial Officer
Rachel Duan - Director
Lise Kingo - Director

Peer Information
Sanofi (AGN.)
Sanofi (ABBV)
Sanofi (NVO)
Sanofi (LLY)
Sanofi (RHHBY)
Sanofi (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 80105N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 2,527.23
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $137,481.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.32%
Current Fiscal Quarter EPS Consensus Estimate: $0.85 Indicated Annual Dividend: $1.26
Current Fiscal Year EPS Consensus Estimate: $4.13 Payout Ratio: 0.34
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.01
Estmated Long-Term EPS Growth Rate: 11.84% Last Dividend Paid: 05/04/2022 - $1.26
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 13.18
Trailing 12 Months: 13.60
PEG Ratio: 1.11
Price Ratios
Price/Book: 1.68
Price/Cash Flow: 10.03
Price / Sales: 3.05
EPS Growth
vs. Year Ago Period: 12.37%
vs. Previous Quarter: 37.97%
Sales Growth
vs. Year Ago Period: 4.82%
vs. Previous Quarter: -5.03%
ROE
03/31/22 - 25.34
12/31/21 - 24.61
09/30/21 - 25.76
ROA
03/31/22 - 14.42
12/31/21 - 14.01
09/30/21 - 14.37
Current Ratio
03/31/22 - -
12/31/21 - 1.44
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - 1.03
09/30/21 - -
Operating Margin
03/31/22 - 22.18
12/31/21 - 21.79
09/30/21 - 21.55
Net Margin
03/31/22 - 17.15
12/31/21 - 16.52
09/30/21 - 16.60
Pre-Tax Margin
03/31/22 - -
12/31/21 - 19.91
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 32.39
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - 2.70
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.25
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - 19.88
09/30/21 - -
 

Powered by Zacks Investment Research ©